Connect with us

BUSINESS

Metatron Inc (OTCMKTS: MRNJ) States Share Repurchase Plan

Published

on

Metatron Inc (OTCMKTS: MRNJ) has announced that its Board of Directors has approved the repurchase of up to 1 billion stocks of the company’s shared stock from time to time on the open marketplace in secretly transferred dealings. 

“The share repurchase sanction imitates our continuing promise to refine the asset worth of the company’s stock,” said CEO Joe Riehl.

Stocks to be repurchased under a Rule 10b5-1 strategy

The company’s management will schedule and amount any stocks repurchased based on its valuation of market conditions and other matters. It may also complete repurchases under a Rule 10b5-1 strategy, which would license stocks to be repurchased when the company might be prohibited from doing so under insider exchange regulations. The repurchase package may be deferred or withdrawn at any time. Any repurchased stocks will be obtainable for usage associated with its stock tactics and for other business determinations.

Metatron to partner Krave Games LLC

In other news, Metatron declared a partnership with Krave Games LLC, directed to the discharge of their first game. The new game is an addicting cosmos-themed mobile game application christened Holo Ball for the iPhone and iPad. Krave transports its advanced mobile game know-how to the table and has admission to the nets of millions of Instagram and social media groups. The two businesses plan to air a collective rollout of diverse mobile submissions geared towards gaming, entertaining, and existence classes.

With the prevalent online occurrence behind Krave games, t Holo Ball’s proclamation responses surpass anticipations, and handlers can’t seem to get adequate. Players having been giving frenzied evaluations on the game and are happy to see the following announcements from the enterprise of Krave and Metatron. Holo Ball has been out for iOS and is presently accessible on the iTunes app repository. Form 1.1 of the game was published on February 18, 2019, and presently has a 5-star score. 

Rendering to Small Biz Daily, the #1 most general iOS Mobile Submissions group is games, and in 2018 games accounted for 76% of the anticipated 92.1 Billion mobile application income. 

[optin-monster-shortcode id="lt2ftjs5qhrst1pzmmap"] *Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

BUSINESS

Lexaria Bioscience Corp (NASDAQ: LEXX) Announces Expansion Of Its Intellectual Property Portfolio

Published

on

Lexaria Bioscience Corp (NASDAQ: LEXX) announced an expansion of its intellectual property portfolio. The news comes after the global innovator in drug delivery platforms was granted its debut patent in Japan.

According to sources, this is the 20th patent granted to the company. With the patent titled “Stable ready-to-drink beverage compositions comprising lipophilic active agents, Lexaria Bioscience Corp is granted patent protection in Japan.

CEO comments on the 20th patent granted to the company

“With our 20th patent granted worldwide, Lexaria continues to demonstrate the versatility of our DehydraTECH drug delivery platform, encouraging innovation in the consumable liquid category around the world,” said Chris Bunka, CEO of Lexaria. “This new patent adds to our existing suite of granted patents spanning the EU, the U.S., India and Australia, and continues to build value for Lexaria shareholders and clients.”

Information about the patent

From the third patent family, this is the third patent granted. As many as 13 patent families have made it to Lexaria’s patent application suite. According to sources, non-psychoactive cannabinoids and NSAIDS are the active ingredients permitted for use under the new patent.

Patent applications progressing at a global level

According to reports, Lexaria Bioscience Corp currently has ongoing patent applications in countries across the globe. News about developments and progress about the patent status will be made available by the company as information becomes available.

DehydraTECH™ is a drug delivery technology that is reportedly used to enhance active pharmaceutical ingredients (APIs) enter the bloodstream. Formulated by Lexaria Bioscience Corp, it enhances the effectiveness of fat-soluble active molecules by reducing the overall dosing. The technology that the company develops can be used in a range of ingestible product formats like foods, beverages, oral suspensions, tablets, and capsules.

According to reports, the introduction of DehydraTECH, with cannabinoids and nicotine, has increased bio-absorption is by up to 5-10x. Additionally, this has also brought down the time of onset from 1-2 hours to minutes.

[optin-monster-shortcode id="lt2ftjs5qhrst1pzmmap"] *Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

BUSINESS

OrganiGram Holdings Inc (NASDAQ: OGI) Reports Gross Revenue Of $29.1 Million For 3Q 2021

Published

on

OrganiGram Holdings Inc (NASDAQ: OGI) recently declared its third-quarter earnings. The company reported gross revenue of $29.1 million for the third quarter of 2021. The corporate house recorded an increase in earnings 39% sequentially to $20.3 million in Q3 this year, from Q2 2021, and 13% from the same prior-year period. The company is a leading licensed producer of cannabis.

Chief Strategy Officer comments on the growth in revenue

“We are pleased with the growth in revenue in Q3 as we were better staffed to fulfill the demand for our revitalized product portfolio, which continues to resonate well with consumers,” said Paolo De Luca, Chief Strategy Officer. “The ongoing investment in our genetics and cultivation program has yielded some exciting new dried flower products with more genetics and derivative product launches planned for the near term. Sales are trending higher to date in Q4 supported by a strong outlook for the industry as the number of cannabis retail stores continues to grow and existing stores are permitted to re-open their doors to customers.”

A plethora of new products launched this year

This year, various products were launched. Starting with March 2021, OrganiGram Holdings Inc introduced its Edison Black Cherry Punch, I.C.C.and Slurricane strains. They were introduced in a package of three half-gram pre-rolls.

In the following month in the same year, GMO Cookies and MAC-1, which are high potency Edison dried flower strains, were introduced by the company. The products contain 20-26% THC range and are available in the market in 3.5g format. They can also be purchased as packages of three half-gram pre-rolls.

Another product was made available in the market in March this year. As part of the Indi portfolio, Skyway Kush, the debut strain which offers a 20% to 23% THC range, was introduced. In June 2021, in 3.5g formats, two Indi dried flower strains were made available at quarter-end. While Biscotti Gelato has a THC range of 20-26%, Gelato #33 has a THC range of 17-23%.

[optin-monster-shortcode id="lt2ftjs5qhrst1pzmmap"] *Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

BUSINESS

Neptune Wellness Solutions Inc (NASDAQ: NEPT) Reported Net Loss of $60.3 Million In Fourth Quarter 2021

Published

on

Neptune Wellness Solutions Inc (NASDAQ: NEPT) a fully integrated wellness company, reported the financial performance for the fourth quarter of 2021 and the year ended 2021. During the fourth quarter, the company reported a loss of $60.3 million, which was higher than the corresponding period last year.

In Red for the second consecutive year: 2021 was the challenging year for the company and industry due to pandemic and transformation activities undertaken by the company. The company reported revenue of $6.8 million for the fourth quarter, and the year ended 2021, the revenue stood at $46.8 million, a 56% growth compared to the revenue in 2020. However, due to pandemic and transformation activities, the cost increased year on year. As a result, the company reported a loss of $24.8 million during the quarter, and for the whole year, the gross loss stood at $36.2 million.

Given the increase in cost, the adjusted EBITDA came in at a negative $24.7 million in the fourth quarter, and for the entire year, it was negative $52.7 million. Loss ad adjusted EBITDA level coupled with an increase in depreciation and interest outgo, the company reported a loss in Q4 2021 and for 2021. The loss at the end of the year stood at $52.7 million. During the quarter, the company raised $55 million by placing the equity with investors.

Guidance:  The company indicated the guidance for the revenue in the range of $10 to $12 million, and the company is well place to achieve top-line growth. Management further indicated, given the cost initiatives taken by Neptune Wellness in the last year, the benefit of the same is expected to come in 2022. In addition, Neptune will continue to drive the growth in its organic brand through innovation and extensive distribution of its products. Further, the company is also looking at acquisitions (acquired majority stake in Sprout Food, baby food brand in the U.S. in Q4 2021), which will drive the earnings immediately. Both these factors should result in higher margins in the medium to long term and ultimately enhanced value for its shareholders.

[optin-monster-shortcode id="lt2ftjs5qhrst1pzmmap"] *Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

Trending Stories